Aurobindo enters domestic formulations space with the acquisition of Veritaz for Rs 171 Cr

Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments

Panacea Biotec sells its domestic formulations business to Mankind Pharma

The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year

Strong show in domestic formulations business by Indian pharma in Q1FY22: Ind-Ra

Domestic business was up 41.9% YoY and 27.7% QoQ

Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%

Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth

Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%

Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth

RPG Life Sciences reports Rs 707.5 crore revenue in FY26, 8% annual growth

In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth

Rubicon forays into India's CNS segment with Rs 175.92 crore Arinna buy

Acquires 85% stake in the formulations company valued at Rs 200 crore enterprise value; founder Vivek Seth to retain 15%

JB Pharma Q3 FY26 PAT up by 22% to Rs. 198 Cr

The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26

JB Pharma Q1 FY26 PAT up at 14% to Rs. 202 Cr

RPG Life Sciences posts Q2 FY25 revenue Up by 12% YoY

Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25